Berlin - Delayed Quote EUR

Medigene AG (MDG1.BE)

1.9550

+0.1450

(+8.01%)

At close: April 19 at 8:04 AM GMT+2

Medigene to Present at Upcoming Scientific Conferences

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been invited to present at the CHI's 8th Annual Immuno-Oncology Summit Europe from April 23-25, 2024, in London, UK, as well as at the 7th International Neoantigen Summit to be held in Amsterdam, Netherlands from April 29 - May 1, 2024. The presentations will be available on Medigene´s website after the c

GlobeNewswire 2 days ago

MDGEF
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024

Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents superior recombinant T cell receptor (rTCR) engineered T cell functionality as well as a favorable safety profile when rTCR-T cells are armored and enhanced with the PD1-41BB costimulatory switch protein (CSP) at the American Association for Cancer Research (

GlobeNewswire 11 days ago

MDGEF
Medigene AG Secures European Patent for its iM-TCR Technology

Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor (iM-TCR) technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell (TCR-T) therapie

GlobeNewswire 15 days ago

MDGEF
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update

Significant corporate and scientific progress in 2023Innovations to End-to-End Platform technologies and IP portfolioPipeline additions with multiple KRAS neoantigen targetsAdvancement of lead program MDG1015 with IND/CTA approval expected in 2H 2024 Partnering expansion with new scientific partnership with the National Cancer Institute and further collaboration for new costimulatory switch protein with Helmholtz MunichUpdates to strategy going forward to develop both TCR-T therapies and additio

GlobeNewswire 22 days ago

MDGEF
We Think Medigene (ETR:MDG1) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Simply Wall St. 24 days ago

MDG1.DE
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Planegg/Martinsried, March 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be participating in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on March 26, 2024. Members of Medigene's management team will join a fireside chat and will be available for virtual one-on-one meetings with registered investors. --- end of press rele

GlobeNewswire last month

MDGEF
Medigene AG to report full year 2023 financial results on March 28, 2024

Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results and provide a corporate update for the fiscal year ended December 31, 2023, on Thursday, March 28, 2024. Following the release of the full year 2023 earnings results and annual report on Medigene’s website, the Company will host a conference call that same day at 3 pm CET / 10 am

GlobeNewswire last month

MDGEF
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting

Planegg/Martinsried, March 6, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present a poster at the American Association for Cancer Research Annual Meeting (AACR) 2024 taking place from April 5-10, 2024 in San Diego, USA as well as an oral presentation at the ELRIG-Forum 2024 to be held in Darmstadt, Germany on March 7, 2024. Poster presentati

GlobeNewswire last month

MDGEF
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo

Planegg/Martinsried, March 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the Japan Patent Office protecting its inducible Medigene T cell receptor (iM-TCR), a control mechanism to regulate efficacy and safety of its T cell receptor engineered T cell (TCR-T) therapies. “We are delighted with the receipt

GlobeNewswire last month

MDGEF
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies

Multiple members of management as expert speakers including Prof. Dr. Dolores Schendel, Chief Scientific Officer of Medigene, Dr. Barbara Lösch, Head of Technology & Innovation and Dr. Kirsty Crame, Vice President, Clinical Strategy & DevelopmentPresentations and seminars highlight key parts of Medigene’s proprietary End-to-End Platform by offering multiple solutions to address the challenges in TCR-T therapy development for treatment of solid tumors Planegg/Martinsried, February 29, 2024. Medig

GlobeNewswire last month

MDGEF
Medigene to Present at Upcoming Conferences

Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the 7th CAR-TCR Summit Europe taking place February 27-29, 2024, in London as well as at the East-West Biopharma Summit to be held March 4-6, 2024, in Singapore. 7th CAR-TCR Summit Europe 2024https://cartcr-europe.com/ Presentation Date: February 28, 202

GlobeNewswire last month

MDGEF
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors

Gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma selected as initial clinical indications for lead program MDG1015MDG1015 is a first-in-class, third generation TCR-T therapy targeting NY-ESO-1/ LAGE-1a, armored and enhanced by costimulatory switch protein PD1-41BB Clinical development in both orphan and more common cancer indications addresses high unmet medical need in large patient populations Planegg/Martinsried, February 12, 2024. Medigene AG (Medigene, FSE:

GlobeNewswire 2 months ago

MDGEF
Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Conference

Planegg/Martinsried, December 19, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be attending the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco to be held from January 8-11, 2024. J.P. Morgan Healthcare Conference https://www.jpmorgan.com/about-us/events-conferences/health-care-conferenceDate: January 8-11, 2024Location: The We

GlobeNewswire 3 months ago

MDGEF
Medigene AG Announces Prioritization of Pipeline and Resource Allocation as well as Extension of Cash Runway

Lead program MDG1015 on track for CTA/IND approval in 2H 2024Prioritization of pipeline to accelerate the advancement of Medigene’s maturing KRAS-libraryProjected cash runway extended to Q1 2025. Exploring financing options to extend cash runway into 2026 and beyond Planegg/Martinsried, November 21, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, tod

GlobeNewswire 4 months ago

MDGEF
Medigene amends 2023 financial guidance

Planegg/Martinsried, November 21, 2023 The Executive Management Board of Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today adjusted financial guidance for fiscal year 2023. The Company maintains its guidance on expected revenues to be between EUR 5 and 7 million in 2023 (unchanged). The Company continuously optimizes its resource allocation based on bu

GlobeNewswire 4 months ago

MDGEF
Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A*11

Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presents novel preclinical data of their MDG2011 program lead candidates which are optimal affinity Kirsten rat sarcoma viral oncogene homologue mutation (mKRAS)-specific T cell receptors (TCRs) targeting human leukocyte antigens (HLA) A*11, in combination with a PD1-41BB

GlobeNewswire 5 months ago

MDGEF
Medigene Reports Financial Results and Corporate Update for Q3 2023

Focus on executing the strategic plan and delivering shareholder valueFirst MDG2011 pre-clinical data support potential in solid tumor therapyExpansion of patent portfolio and license agreement for technologies in our End-to-End Platform Guidance confirmed; cash runway maintained through Q4 2024 Planegg/Martinsried, October 26, 2023. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunoth

GlobeNewswire 5 months ago

MDGEF
AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product

SEATTLE, October 25, 2023--AGC Biologics is providing autologous clinical production for Medgine's therapy product focused on the treatment of solid cancers.

Business Wire 5 months ago

MDGEF
Medigene presents first pre-clinical data of optimal affinity TCR targeting mKRAS G12V combined with a PD1-41BB costimulatory switch protein showing enhanced and sustained tumor killing

Planegg/Martinsried, October 23, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard) an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, presents data showing significantly enhanced T cell activity when combining the PD1-41BB costimulatory switch protein (CSP) with recombinant T cell receptors (rTCR) not only when directed at the cancer-testis antigen (CTA) New York esophageal squamous cell carcinoma-1 (NY-E

GlobeNewswire 5 months ago

MDGEF
Medigene to present new pre-clinical data for pipeline TCR-T therapies at the ESMO Congress 2023

Planegg/Martinsried, October 16, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the ESMO Congress 2023 being held on October 20-24, 2023, in Madrid, Spain. The data to be presented shows that optimal affinity T cell receptors (TCRs) when combined with Medigene’s PD1-41BB costimulatory switch protein (CSP), provides strong protect

GlobeNewswire 6 months ago

MDGEF

Performance Overview

Return	MDG1.BE	DAX PERFORMANCE-INDEX
YTD	+29.90%	+5.88%
1-Year	+8.31%	+11.68%
3-Year	-49.15%	+14.73%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Medigene AG (MDG1.BE)

Medigene to Present at Upcoming Scientific Conferences

Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024

Medigene AG Secures European Patent for its iM-TCR Technology

Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update

We Think Medigene (ETR:MDG1) Needs To Drive Business Growth Carefully

Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Medigene AG to report full year 2023 financial results on March 28, 2024

Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting

Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo

Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies

Medigene to Present at Upcoming Conferences

Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors

Medigene AG to attend at the 42nd Annual J.P. Morgan Healthcare Conference

Medigene AG Announces Prioritization of Pipeline and Resource Allocation as well as Extension of Cash Runway

Medigene amends 2023 financial guidance

Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A*11

Medigene Reports Financial Results and Corporate Update for Q3 2023

AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product

Medigene presents first pre-clinical data of optimal affinity TCR targeting mKRAS G12V combined with a PD1-41BB costimulatory switch protein showing enhanced and sustained tumor killing

Medigene to present new pre-clinical data for pipeline TCR-T therapies at the ESMO Congress 2023

Performance Overview